Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10557190 | 0.90 | SMN1; SMN2 (0.43) | RAPGEF4ALDH1A1MAPTSMN1; SMN2HDAC4 | |
| SCHEMBL10551933 | 0.86 | HDAC3 (0.41) | RAPGEF4ALDH1A1MAPTSMN1; SMN2HDAC4 | |
| SCHEMBL10557801 | 0.86 | HDAC3 (0.41) | RAPGEF4ALDH1A1MAPTSMN1; SMN2HDAC4 | |
| SCHEMBL10388289 | 0.85 | GRIN2D (0.47) | ALDH1A1HDAC4GAASIGMAR1GRIN2D | |
| SCHEMBL10555331 | 0.85 | RAPGEF4 (0.38) | RAPGEF4ALDH1A1MAPTSMN1; SMN2HDAC4 | |
| SCHEMBL10133361 | 0.84 | ALDH1A1 (0.52) | RAPGEF4ALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL10559062 | 0.83 | SMN1; SMN2 (0.39) | RAPGEF4ALDH1A1MAPTSMN1; SMN2HDAC4 | |
| SCHEMBL10558831 | 0.83 | SIGMAR1 (0.43) | RAPGEF4ALDH1A1MAPTSMN1; SMN2HDAC4 | |
| SCHEMBL7351056 | 0.82 | HDAC4 (0.47) | ALDH1A1HDAC4MEF2D | |
| SCHEMBL5543436 | 0.81 | LPL (0.47) | HDAC4MEF2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-3795568-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019043214-A1 | GLUTARIMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| EP-2862859-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-8735425-B2 | Tetrahydroisoquinoline derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2256105-B1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2256105-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| EP-0147379-A1 | Making nitrodiarylamines | MONSANTO COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4252943-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4228103-A | Effecting condensation of nitrohaloarene and formyl derivative of a primary aromatic amine with alkali metal hydroxide | MONSANTO COMPANY (US) | 1980-10-14 | — | — | US | disclosed |
| US-4217359-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4209463-A | Promoting the formation of nitrodiarylamines from nitrohaloarenes, activated aryl amines and sodium carbonates | MONSANTO COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
| US-4196146-A | Making nitrodiarylamines from formyl derivatives of aromatic amines and nitrohaloarenes by admixing with certain aqueous salt solutions | MONSANTO COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4187248-A | FORMANILIDE | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4187249-A | COMPOUNDS OF POTASSIUM, CESIUM, OR RUBIDIUM | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4140716-A | Process for making an amide of formic acid and forming nitrodiarylamine therefrom | MONSANTO COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DGAT1, DGAT2, DLAT | RAPGEF4 1371/4885ALDH1A1 789/4885MAPT 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.